Stephen Dilly, Sierra Oncology CEO
May 2, 2022 02:59 PM EDTUpdated May 3, 06:57 AM
Deals
Pharma

GSK beat six oth­er com­pa­nies to the Sier­ra deal ta­ble and pre­vailed af­ter ini­tial $46 per share bid

Kyle LaHucik

Senior Reporter

With­in weeks of Sier­ra On­col­o­gy re­veal­ing it had tak­en a failed Gilead JAK in­hibitor and turned it in­to a Phase III suc­cess, Glax­o­SmithK­line swooped in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times